A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With Fibromyalgia

Phase 2TerminatedNCT03965091

Teva Branded Pharmaceutical Products R&D, Inc.189 enrolled

Overview

The primary objective of the study is to estimate the treatment effect of fremanezumab administered subcutaneously (SC) in reducing pain in adult participants with fibromyalgia (FM). A secondary objective is to evaluate the effect of fremanezumab on other efficacy measures, including pain, quality of life, sleep, fatigue, improvement in health, physical functioning, and mood. Another secondary objective is to evaluate the safety and tolerability of fremanezumab administered SC in adult participants with FM. The total duration of participant participation in the study is planned to be 21 weeks, consisting of a screening period of up to 5 weeks (ranging from 17 to 35 days), and a double-blind treatment period of 16 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

189

Conditions

Fibromyalgia

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * approved for study participation by the Fibromyalgia Eligibility Review Committee * body mass index of 18.5 to 45 kilograms (kg)/square meter (m\^2) and a body weight ≥45 kg * agree to use only acetaminophen as rescue medication for FM-related pain (up to 1000 mg per dose and not to exceed 3000 mg/day for any indication throughout the study period) * non-pharmacologic interventions (including normal daily exercise routines, chiropractic care, physical therapy, psychotherapy, and massage therapy) are unchanged for a minimum of 30 days prior to screening and will remain unchanged throughout the study * agree to maintain a usual and unchanged physical exercise regimen * must be of nonchildbearing potential or, defined as: * women surgically sterile by documented complete hysterectomy, bilateral oophorectomy, or * bitubal ligations or confirmed to be postmenopausal (at least 1 year since last menstrual period) and * menopausal women confirmed by a follicle-stimulating hormone \>35 units (U)/liter (L) * men surgically sterile by documented vasectomy OR If of childbearing potential, patients must meet any of the following criteria: * must use highly effective contraception method with their partners during the entire study period and for 5 months after the last dose of the study drug. * sexual abstinence is only considered a highly effective method if defined as refraining from heterosexual intercourse in the defined period. * female participants of childbearing potential must have a negative serum beta-human chorionic gonadotropin (β-HCG) pregnancy test at screening (confirmed by urine dipstick β-HCG pregnancy test at baseline). * must agree not to participate in another interventional study from the screening period through the end of study (EOS) visit o Additional criteria apply, please contact the investigator for more information Exclusion Criteria: * unable or unwilling to discontinue/washout of prohibited medications * ongoing pain that would confound or interfere with the assessment of the participant's FM pain or require excluded therapies during the participant's participation in this study. * surgery planned during the study period * receiving prophylactic treatment for migraine-related disorders, including topiramate, valproic acid, onabotulinumtoxinA, amitriptyline, and nortriptyline * known history of clinically significant or unstable hematologic, cardiac, or thromboembolic events * known history of suicide attempt, suicidal behavior, or suicidal ideation within the last 12 months * lifetime history of any psychotic and/or bipolar disorder * current, untreated, moderate or severe major depressive disorder and/or anxiety * known history of hypersensitivity reactions to injected proteins, including monoclonal antibodies (mAbs) and animal venoms, or a history of Stevens-Johnson Syndrome/toxic epidermal necrolysis syndrome o Additional criteria apply, please contact the investigator for more information

Locations (49)

Teva Investigational Site 14159

Birmingham, Alabama, United States

Teva Investigational Site 14174

Huntsville, Alabama, United States

Teva Investigational Site 14431

Mesa, Arizona, United States

Teva Investigational Site 14166

Oceanside, California, United States

Teva Investigational Site 14435

Panorama City, California, United States

Outcomes

Primary Outcomes

Change From Baseline in the Weekly Average of the Daily Average Pain Intensity-Numerical Rating Scale (PI-NRS) Score Over the Past 24 Hours at Week 12

The PI-NRS is an 11-point pain intensity numerical rating scale where 0=no pain and 10=worst possible pain; higher scores indicating more pain. Weekly average of the daily average PI-NRS pain score over the past 24 hours was derived using formula: Summation of non-missing efficacy variable in an analysis week divided by the number of days with non-missing efficacy variable in the analysis week. Baseline was defined as the last 14 days before the first dose of study drug.

Time frame: Baseline, Week 12

Secondary Outcomes

Change From Baseline in the Individual Components of the Fibromyalgia Impact Questionnaire Revised (FIQR) Score: Symptom Subscore, Impact Subscore, and Functional Subscore at Week 12

The FIQR is a commonly used instrument in the evaluation of fibromyalgia participants. It contains 21 questions in 3 domains: function (9 questions), overall impact (2 questions), and symptoms (10 questions). Questions are graded on a 0 to 10 numeric scale with 10 being the worst. All questions are framed in the context of the last 7 days. The sub-total score for each domain is the summation of scores in the domain. The function sub-total score ranges from 0 (better) to 90 (worst), with a lower score indicating better (higher) function; overall impact sub-total score ranges from 0 to 20, with a lower score indicating better (lower) impact; the symptoms sub-total score ranges from 0 to 100, with a lower score indicating a better (lower) level of symptoms. Baseline was defined as the last 14 days before the first dose of study drug.

Time frame: Baseline, Week 12

Responder Rate of the Patient Global Impression of Change (PGIC) Rating: Number of Participants Who Were Much Improved or Very Much Improved at Week 12

The PGIC scale evaluates all aspects of participants' health and assesses if there has been an improvement or decline in clinical status since the start of the study. Participants recorded responses to the PGIC scale at Week 12. Improvement was recorded on a 7-point scale, with 1 = very much improved, 2 = Much Improved, 3 = Minimally Improved, 4 = No Change, 5 = Minimally Worse, 6 = Much Worse, and 7 = Very Much Worse. Scale "much improved" or "very much improved" were considered improved.

Time frame: Week 12

Number of Participants Who Experienced ≥30% Reduction From Baseline in Weekly Average of Daily Average PI-NRS Score at Week 12

The PI-NRS is an 11-point pain intensity numerical rating scale where 0=no pain and 10=worst possible pain; higher scores indication more pain. Weekly average of the daily average PI-NRS pain score over the past 24 hours was derived using formula: Summation of non-missing efficacy variable in an analysis week divided by the number of days with non-missing efficacy variable in the analysis week.

Time frame: Week 12

Number of Participants Who Experienced ≥50% Reduction From Baseline in Weekly Average of Daily Average PI-NRS Score at Week 12

Time frame: Week 12

Change From Baseline in the Weekly Average of Daily Worst PI-NRS Score Over Past 24 Hours at Week 12

The PI-NRS is an 11-point pain intensity numerical rating scale where 0=no pain and 10=worst possible pain; higher scores indication more pain. Weekly average of the daily worst PI-NRS pain score over the past 24 hours was derived using formula: Summation of non-missing efficacy variable in an analysis week divided by the number of days with non-missing efficacy variable in the analysis week. Baseline was defined as the last 14 days before the first dose of study drug.

Time frame: Baseline, Week 12

Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Short Form (SF) 8a T-score at Week 12

The PROMIS SF8a scale contains 8 items and assesses sleep disturbance over the past 7 days. One item assessing overall sleep quality use a scale of very poor, poor, fair, good, or very good. Other 7 items use a scale of not at all, a little bit, somewhat, quite a bit, or very much. Each item of the PROMIS sleep disturbance SF8a is on 5-point scales (1 to 5), with 1 for the lowest sleep disturbance and 5 for the highest sleep disturbance. The total score ranging from 8 (lowest sleep disturbance) to 40 (highest sleep disturbance) was calculated as the summation of 8 non-missing scores. T-score was calculated from the total raw score using the scoring table (PROMIS-Sleep Disturbance Scoring Manual) with a mean of 50 and a standard deviation of 10. Possible range for T-score is 30 to 80, with higher scores indicating greater severity of sleep impairment.

Time frame: Baseline, Week 12

Change From Baseline in the PROMIS Physical Function SF 12a Scale Score at Week 12

The PROMIS physical function scale measures self-reported capability. This includes the functioning of one's upper extremities (dexterity), lower extremities (walking or mobility), and central regions (neck, back), as well as instrumental activities of daily living, such as running errands over the past 7 days. A single physical function capability score is obtained from a SF. The PROMIS physical function SF12a scale contains 12 items with 5-point scales (1 \[not at all\] to 5 \[very much\]) for each item with a total score ranging from 12 (poor physical function) to 60 (better physical function). A higher score indicates greater level of physical capability. Total raw score was calculated as the summation of 12 non-missing scores for participants who can walk 25 feet or summation of 6 non-missing scores for participants who cannot walk for 25 feet. The calculated total raw score was converted into scale score using the scoring tables (PROMIS-Physical Function Scoring Manual).

Time frame: Baseline, Week 12

Change From Baseline in the PROMIS Fatigue SF 8a T-Score at Week 12

The PROMIS Fatigue SF8a contains 8 items with 5-point scales (1 \[never\] to 5 \[always\]) for each item over the past 7 days. The total raw score ranges from 8 (lowest level of fatigue) to 40 (highest level of fatigue) was calculated as the summation of 8 non-missing scores. T-score was calculated from the total raw score using the scoring table (PROMIS-Fatigue Scoring Manual) with a mean of 50 and a standard deviation of 10; scores higher than 50 indicate greater fatigue compared to the reference population.

Time frame: Baseline, Week 12

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse events (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. Any AE occurring on or after the first dose of study drug is considered a treatment-emergent AE (TEAE). A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.